To take your ideas to Policymakers, Join the Campaign of #PolicyPulse Write to feedback@policypulse.com

India's pharma market declines to a 2-year low

India’s FDC market dipped 14.6 percent and is now valued at Rs 196 crore

Policy Pulse
Publish Date: Jun 10 2016 2:35PM | Updated Date: Jun 10 2016 2:35PM

India's pharma market declines to a 2-year low

 Demo photo

 

 
This May, Indian pharmaceuticals market's growth has been the lowest in last two years, stuck by a drop in sales of fixed dose combination drugs, lower-than-expected uptake and fresh price cuts, as per pharmaceutical market research company AIOCD PharmaTrack. 
 
According to a ‘The Economic Times’ report, pharmaceuticals market grew by 7.7 percent for May as against  11.6 percent during the same month in 2015, reaching sales of Rs 99,476 crore over a 12-month period based on Moving Annual Total (MAT), an agency release said. 
 
India’s FDC market dipped 14.6 percent and is now valued at Rs 196 crore and anti-infectives, derma and respiratory were the worst-hit sections, it further. 
 
Fixed dose combination (FDC) drugs are products that have a mixture of two or more therapeutic ingredients in a single dose. 
 
Drug makers in country were more affected by drop in volumes in FDCs than MNC rug makers in the country, as per PharmaTrack. 
 
At the same time, products other than FDCs increased at 8.4 percent, showing a somewhat better growth rate in May than for the month of April, the firm added. 
 
Sales of FDCs have seen a dip since March, when health ministry announced banning the immediate manufacture, sale and distribution of 344 combination drugs. 
 
Over 100 combination drug makers have challenged government's decision to ban products at the Delhi High Court.